{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:10:00Z","timestamp":1761059400311},"reference-count":12,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2012]]},"DOI":"10.3960\/jslrt.52.145","type":"journal-article","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T23:00:49Z","timestamp":1349132449000},"page":"145-147","source":"Crossref","is-referenced-by-count":9,"title":["Disappearance of Both the BCR\/ABL1 Fusion Gene and the JAK2V617F Mutation with Dasatinib Therapy in a Patient with Imatinib-Resistant Chronic Myelogenous Leukemia"],"prefix":"10.3960","volume":"52","author":[{"given":"Koiti","family":"Inokuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Scott LM, Campbell PJ, Baxter EJ, Tony Todd T, Stephens P, <I>et al<\/I>.: The V617F <I>JAK2<\/I> mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106:2920-2921, 2005","DOI":"10.1182\/blood-2005-05-2087"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Kramer A, Reiter A, Kruth J, Erben P, Hochhaus A, <I>et al<\/I>.: JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 8:658-660, 2007","DOI":"10.1016\/S1470-2045(07)70206-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, <I>et al<\/I>.: Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting <I>BCR<\/I><I>-ABL<\/I> translocation and JAK2<SUP>V617F<\/SUP> mutation. Blood 109:4106-4107, 2007","DOI":"10.1182\/blood-2006-12-061135"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Conchon MR, Costa JL, Novaes MM, Dorlhiac-Llacer PE, de Alencar Fischer Chamone D, <I>et al<\/I>.: Simultaneous detection of JAK2 V617F mutation and bcr-abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol 88:243-245, 2008","DOI":"10.1007\/s12185-008-0131-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, <I>et al<\/I>.: Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 32:1608-1610, 2008","DOI":"10.1016\/j.leukres.2008.03.004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, <I>et al<\/I>.: Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 21:1103-1104, 2007","DOI":"10.1038\/sj.leu.2404591"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Haq AU: Transformation of polycythemia vera to Ph-positive chronic myelogenous leukemia. Am J Hematol 35:110-113, 1990","DOI":"10.1002\/ajh.2830350209"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Oehler L, Jaeger E, Eser A, Sillaber C, Gisslinger H, <I>et al<\/I>.: Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera <I>in vitro<\/I>. Blood 102:2240-2242, 2003","DOI":"10.1182\/blood-2003-03-0676"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Silver RT: Imatinib mesylate (Gleevec<SUP>TM<\/SUP>) reduces phlebotomy requirements in polycythemia vera. Leukemia 17:1186-1187, 2003","DOI":"10.1038\/sj.leu.2402938"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Shah NP, Tran C, Lee FY, Chen P, Norris D, <I>et al<\/I>.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401, 2004.","DOI":"10.1126\/science.1099480"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, <I>et al<\/I>.: Discovery of <I>N<\/I>-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumour activity in preclinical assays. J Med Chem 47:6658-6661, 2004","DOI":"10.1021\/jm049486a"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Wappl M, Jaeger E, Streubel B, Gisslinger H, Schwarzinger I, <I>et al<\/I>.: Dasatinib inhibits progenitor cell proliferation from polycythaemia vera. Eur J Clin Invest 38:578-584, 2008","DOI":"10.1111\/j.1365-2362.2008.01982.x"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:46:07Z","timestamp":1621539967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/52\/2\/52_145\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.52.145","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}